Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Transfusion Requirements in Surgical Oncology Patients

2014; Lippincott Williams & Wilkins; Volume: 122; Issue: 1 Linguagem: Inglês

10.1097/aln.0000000000000511

1528-1175

Juliano Pinheiro de Almeida, Jean‐Louis Vincent, Filomena Regina Barbosa Gomes Galas, Elisângela Pinto Marinho de Almeida, Júlia Tizue Fukushima, E Osawa, F Bergamin, Clarice Lee Park, Rosana Ely Nakamura, Silvia Moulin Ribeiro Fonseca, Guilherme Cutait, Joseane Inacio Alves, Mellik Bazan, Sílvia Regina Rios Vieira, Ana C. Vieira Sandrini, Henrique Palomba, Ulysses Ribeiro, Alexandre Crippa, Marcos F. Dall’Oglio, Maria Del Pilar Estevez Diz, Roberto Kalil Filho, José Otávio Costa Auler Júnior, Andrew Rhodes, Ludhmila Abrahão Hajjar,

Sepsis Diagnosis and Treatment

Several studies have indicated that a restrictive erythrocyte transfusion strategy is as safe as a liberal one in critically ill patients, but there is no clear evidence to support the superiority of any perioperative transfusion strategy in patients with cancer.In a randomized, controlled, parallel-group, double-blind (patients and outcome assessors) superiority trial in the intensive care unit of a tertiary oncology hospital, the authors evaluated whether a restrictive strategy of erythrocyte transfusion (transfusion when hemoglobin concentration <7 g/dl) was superior to a liberal one (transfusion when hemoglobin concentration <9 g/dl) for reducing mortality and severe clinical complications among patients having major cancer surgery. All adult patients with cancer having major abdominal surgery who required postoperative intensive care were included and randomly allocated to treatment with the liberal or the restrictive erythrocyte transfusion strategy. The primary outcome was a composite endpoint of mortality and morbidity.A total of 198 patients were included as follows: 101 in the restrictive group and 97 in the liberal group. The primary composite endpoint occurred in 19.6% (95% CI, 12.9 to 28.6%) of patients in the liberal-strategy group and in 35.6% (27.0 to 45.4%) of patients in the restrictive-strategy group (P = 0.012). Compared with the restrictive strategy, the liberal transfusion strategy was associated with an absolute risk reduction for the composite outcome of 16% (3.8 to 28.2%) and a number needed to treat of 6.2 (3.5 to 26.5).A liberal erythrocyte transfusion strategy with a hemoglobin trigger of 9 g/dl was associated with fewer major postoperative complications in patients having major cancer surgery compared with a restrictive strategy.